Regeneron Pharmaceuticals Inc.
Company Snapshot
Company Overview
Regeneron Pharmaceuticals is a biotechnology company that develops and manufactures products to help patients with allergic and inflammatory diseases, eye diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, hematologic conditions, and rare diseases.
Regeneron Pharmaceuticals has partnerships with various companies, including Sanofi, Bayer, Alnylam Pharmaceuticals, Intellia, and Decibel Therapeutics. For antibody drugs, the company has global development and commercialization with Sanofi for products including Dupixent, Kevzara, and itepekimab. Regeneron has developed VelociSuite, a suite of patented technologies, including VelocImmune, VelociGene, and VelociMab, to identify the best targets for antibody drug development. Regeneron Pharmaceuticals has approximately 35 products in the clinical development pipeline.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Regeneron Pharmaceuticals Inc. In Reports
Regeneron Pharmaceuticals Inc. In News
Company's Business Segments
- Net product sales : This segment inclues revenue generated form the sales of products like EYLEA HD, Libtayo, Praluent, REGEN, Evkeeza and many others.
- Collaboration revenue : This segment inclues income derived from the other brands for collaboration like Sanofi, Bayer, Roche and others.
- Other revenue : Other revenue is the income derived from the non core business activities.
Applications/End User Industries
- Immune System
- Clinical Trials
- Physicians
- Scientists
- Pharmaceuticals
- Hospitals
- Healthcare
- Clinics
- Infectious Diseases
- Clinical Research
- Cardiovascular
- Metabolic
- Therapeutics
- Cancer Care
- Pandemic
- Antibody
- Atopic Dermatitis
- Eye Diseases